BSE · 530057
Vivanza Biosciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹-0 Cr — a -4.7% net margin, versus 0.36% the period before.
Shareholding
As of 2026-03-31
- Promoter20.02%
- Public79.98%
- DII0%
19,461 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.79× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #463 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,93,459 Cr | 24.35 | 4.83 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,50,959 Cr | 381.38 | 10.26 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,60,247 Cr | 92.84 | 22.94 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹93,790 Cr | 1212.96 | 65.21 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,703 Cr | 56.97 | 6.83 | 11.32% | 6.61% |
| Premier Energies Limited | ₹47,038 Cr | 102.19 | 10.9 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,019 Cr | 109.72 | 7.44 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,364 Cr | 238.34 | 21.5 | 19.61% | 8.72% |
| Redington Limited | ₹22,472 Cr | 57.38 | 2.21 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,620 Cr | 210.96 | 10.36 | 14.16% | 8.36% |
| Vivanza Biosciences Limited(this company) | ₹8 Cr | 19.4 | 1.78 | 9.05% | 34.51% |
AI analysis
AI-generated · google/gemini-2.5-flashVivanza Biosciences Limited is listed with a market capitalization of Rs 7 Cr. The company reported a revenue of Rs 7.48 Cr and a profit margin of 34.5%. Its Price-to-Earnings ratio stands at 18.2, with an EPS of 0.1. The debt-to-equity ratio is 1.61.
Positives
- +The trailing twelve-month profit margin is 34.5%, indicating high profitability.
- +The Return on Equity (ROE) is 9.05%, reflecting efficient use of shareholder funds.
- +The Return on Capital Employed (ROCE) is 5.66%, demonstrating decent capital efficiency.
Negatives
- −The promoter holding is low at 20.02%, which could impact confidence.
- −The debt-to-equity ratio is 1.61, indicating a high reliance on debt.
- −Net profit in March 2026 was negative at -0.45 Cr, following a negative net profit of -1 Cr in March 2025.
- −Quarterly revenue has been highly volatile, ranging from Rs 0.48 Cr to Rs 55.36 Cr.
Financial performance
For the quarter ending March 2026, Vivanza Biosciences Limited reported revenue of Rs 6.36 Cr and a net loss of Rs -0.45 Cr. This follows a revenue of Rs 45.25 Cr and a net profit of Rs 0.2 Cr in the preceding quarter (December 2025). Over the quarters of 2025, revenue fluctuated significantly, from Rs 0.48 Cr in March 2025 to Rs 55.36 Cr in September 2025.
Profitability & returns
The company’s profit margin is 34.5%. Return on Equity (ROE) is 9.05%, while Return on Capital Employed (ROCE) is 5.66%. The earnings per share (EPS) is 0.1. The Price-to-Earnings (P/E) ratio stands at 18.2.
Balance sheet
Vivanza Biosciences Limited has a book value of Rs 1.09 per share. The debt-to-equity ratio is 1.61, indicating that the company uses a considerable amount of debt to finance its assets. Currently, the company does not offer a dividend yield.
Ownership & pledges
Public shareholding is at 79.98%, with institutional investors, including DIIs, holding 0.0015%. There are 19,461 shareholders. There are no pledged promoter shares.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Vivanza Biosciences Limitedshare price & fundamentals